Abstract：Objective: To explore the effect of Rapamycin (Rapa) on proliferation and apoptosis of JAK2 V617F positive HEL cells and the expression of programmed death receptor 1 and its ligand (PD-1/PD-L1). Methods: Human erythroleukemia HEL cells with JAK2 V617F mutation positive were cultured in vitro. Rapa with concentrations of 10nm, 50nm and 100nm were added respectively. The control group was established. The inhibition rate of cell proliferation was detected by CCK-8. Caspase 3 / 7 activity detection kit was used to detect the caspase 3/7 activity of cells in each group, Transwell chamber was used to observe the cell migration ability of each group, flow cytometry was used to detect the apoptosis and PD-1 / PD-L1 expression of cells in each group, real-time fluorescence quantitative polymerase chain reaction was used to detect the mRNA changes of JAK2, PD-1 and PD-L1 in cells in each group, and Western blot was used to detect the expression of mammalian rapamycin target protein (mTOR) in each group. Five healthy volunteers were selected. Their lymphocytes were isolated and co cultured with HEL cells. Different concentrations of Rapa were added. The number of Treg cells in each group was detected by flow cytometry. Results: Results of CCK-8 showed that:The inhibition rates of cell proliferation at 72h with different final concentrations of Rapa (10 nM, 50 nM, 100 nM) were (33.33±4.6)%, (49.12±3.72)%, (55.16±4.14)%(P<0.05), respectively. Rapa treated HEL cells at concentrations of 50nM and 100nM after 24h,Caspase 3/7 activity was significantly increased compared with control(P<0.05).The results of flow cytometry showed that the apoptotic rate increased significantly compared with the control.PD-L1 expression was significantly decreased compared with the control(P<0.05).The mRNA expression of JAK2 and PD-L1 was significantly downregulated compared with the control (P<0.01).Healthy volunteer lymphocytes co-cultured with HEL cells for 24h showed an increase in Treg cells(P<0.05).Rapa could reduce Treg cells in a dose-dependent manner.Western blot showed that Rapa was able to inhibit mTOR expression in a dose-dependent manner. Conclusion: Rapa may interfere with the JAK2 pathway by affecting mTOR, which leads to the inhibition of Hel cell proliferation, the reduction of PD-L1 expression, and the suppression of Treg cells.
[1] Liu B,Arakawa Y,Yokogawa R,et al.PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes[J].PLS One,2018,13(4):e194594. [2] 刘贵敏,张丽军,付建珠,等.Ruxolitinib对JAK2V617F阳性骨髓增殖性肿瘤细胞基质金属蛋白酶调控的研究[J].中华血液学杂志,2017,38(2):140~145. [3] 成志勇,张丽军,徐倩,等.JAK-STAT通路在肿瘤发病中的研究进展[J].生理科学进展,2017,48(2):127~131. [4] Liu W,Yu W-M,Zhang J, et al.Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations[J].Leukemia,2017,31(6):1415~1422. [5] Bartalucci N,Calabresi L,Balliu M,et al.JAK2V617 FInhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in mutated cells through PP2A/CIP2A axis.[J].Oncotarget,2017,8(57):96710~96724. [6] Hao X,Xing W,Yuan JJ,et al.Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms[J].Invest New Drugs,2020,38(3):610~620. [7] Lei QY,Wang D,Sun K,et al.Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.[J].Front Cell Dev Biol,2020,8(1):672. [8] 成志勇,张丽军,付建珠,等.PD-1/PD-L1及Treg细胞在JAK2V617F阳性骨髓增殖性肿瘤中的表达及意义[J].中山大学学报(医学科学版),2019,40(1):98~103. [9] Tong GL,Cheng BR,Li JZ,et al.MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells[J].Cancer Med,2019,8(16):7044~7054.
2022, Vol. 28 
冀公网安备13080202000677号